Pattern of Immunocompetent Peripheral Blood Cell Subpopulations in B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

EG Kuzmina, TYu Mushkarina, TV Konstantinova, SV Zatsarenko, SV Shakhtarina, AYu Terekhova, NA Falaleeva, LYu Grivtsova

AF Tsyb Medical Radiological Research Centre, branch of the NMRC of Radiology, 4 Koroleva str., Obninsk, Kaluga Region, Russian Federation, 249036

For correspondence: Svetlana Valer’evna Zatsarenko, 4 Koroleva str., Obninsk, Kaluga Region, Russian Federation, 249031; e-mail: vesper04@mail.ru

For citation: Kuzmina EG, Mushkarina TYu, Konstantinova TV, et al. Pattern of Immunocompetent Peripheral Blood Cell Subpopulations in B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical oncohematology. 2020;13(4):395–405. (In Russ).

DOI: 10.21320/2500-2139-2020-13-4-395-405


ABSTRACT

Background. In the WHO classification small lymphocytic lymphoma (SLL) and B-cell chronic lymphocytic leukemia (В-CLL) are combined into one nosological entity of lymphoid tumors due to their similar tumor cell immunophenotype. Up to now, there is no consensus on either their similarities or the differences between them. Distinction between В-CLL and SLL is drawn with respect to clinical and hematological manifestations of tumors. The reason for the differences that determine tumor spreading in a patient may lie in specific states of some immune system components. Comparison of immune system parameters within the CLL/SLL model provides a unique opportunity to trace the behavior of immunity indicators in local und disseminated pathogenetically similar neoplastic processes and to identify possible prognostic factors.

Aim. To compare quantitative representations of peripheral blood lymphocyte subpopulations in SLL and В-CLL.

Materials & Methods. Immunocompetent cells (relative and absolute Т- and NK-cell counts), immunophenotype, and tumor clone volume were assessed using multicolor flow cytometry based on the expression of СD3, CD4, CD8, CD16, CD19, CD20, CD23, CD5, CD79b, FMC7, CD22, CD43, CD38 antigens, and immunoglobulins light chain Igκ and Igλ. Before chemotherapy onset, the data of 17 SLL and 81 CLL patients (22 of them with B-lymphocyte count of 35–79 % and 59 with 80–99 %) were compared. As a control, peripheral blood lymphocyte subpopulations in 50 relatively healthy individuals (blood donors) were analyzed.

Results. The analysis of NK-cells and Т-lymphocyte subpopulations in SLL showed the preserved number of killer/cytotoxic cells of innate and adaptive immunity (CD16+, CD8+), the reduction of CD4+ Т-cell count, and CD4/CD8 ratio. In CLL a considerable increase of main subpopulations of residual normal lymphocytes was detected. However, the extent of their increase proved to be considerably lower than increase in the volume of tumor B-cell clone, which signifies a rising exhaustion of immune system effector components.

Conclusion. The present study yielded characteristic features of residual normal lymphocyte subpopulations in SLL and CLL with different leukocytosis grades. SLL patients demonstrated the reduction of relative and absolute Т-cell counts with Т-helper (CD3+, СD4+) phenotype, and the increase of cytotoxic CD8+ Т-cells and NK-cells. Lymphocytosis (35–79 %) in the CLL-I group was due not only to tumor В-cells but also to Т-killer (CD16+, CD8+) and Т-helper (CD4+) absolute counts, which were 1.7–2.5 times higher than in SLL and the control group. Residual lymphocyte subpopulation pattern (80–99 %) in the CLL-II group compared with the control group was characterized by a significantly higher absolute count of CD8+ T-cells and CD16+ NK-cells, as well as higher Т-regulatory index compared with SLL and CLL-I groups. These data point to the necessity for further and more detailed study of residual lymphocyte subpopulation pattern within the CLL/SLL model in order to identify additional predisposing factors.

Keywords: chronic lymphocytic leukemia/small lymphocytic lymphoma, tumor B-cell clone, peripheral blood lymphocyte subpopulations, flow cytometry.

Received: April 22, 2020

Accepted: August 30, 2020

Read in PDF


REFERENCES

  1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2016. pp. 121–32.

  2. Луговская С.А., Почтарь М.Е. Гематологический атлас. 4-е издание, дополненное. М.: Триада, 2016. 434 с. [Lugovskaya SA, Pochtar ME. Gematologicheskii atlas. (Hematology Atlas.) 4th revised edition. Moscow: Triada Publ.; 434 p. (In Russ)]

  3. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М., 2018. 356 с. [Poddubnaya IV, Savchenko VG, eds. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. (National Russian guidelines on diagnosis and treatment of lymphoproliferative disorders.) Moscow; 2018. 356 р. (In Russ)]

  4. Луговская С.А., Козинец Г.И. Гематология пожилого возраста. М.: Триада, 2010. 193 с. [Lugovskaya SA, Kozinets GI. Gematologiya pozhilogo vozrasta. (Hematology of the elderly.) Moscow: Triada Publ.; 2010. 193 p. (In Russ)]

  5. Tees MT, Flinn IW. Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. Expert Rev Hematol. 2017;10(2):137–46. doi: 10.1080/17474086.2017.1270203.

  6. Tibaldi E, Brunati AM, Zonta F, et al. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2011;25(11):1768–81. doi: 10.1038/leu.2011.152.

  7. Williams JF, Petrus MJ, Wright JA, et al. Fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous FasL-expressing T cells. Br J Haematol. 1999;107(1):99–105. doi: 1046/j.1365-2141.1999.01670.x.

  8. Захаров С.Г., Голенков А.К., Мисюрин А.В. и др. Экспрессия основных генов внешнего пути апоптоза у больных с впервые выявленным хроническим лимфолейкозом в сравнении с клиническими данными. Российский биотерапевтический журнал. 2018;17(2):41–6. doi: 10.17650/1726-9784-2018-17-2-41-46. [Zakharov SG, Golenkov AK, Misyurin AV, et al. Expression of the apoptosis-releated genes in patients with newly diagnosed chronic lymphocytic leukemia in clinical data context. Russian Journal of Biotherapy. 2018;17(2):41–6. doi: 10.17650/1726-9784-2018-17-2-41-46. (In Russ)]

  9. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956–64. doi: 10.1038/sj.leu.2404584.

  10. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56. doi: 1182/blood-2007-06-093906.

  11. Купрышина Н.А., Тупицын Н.Н. Проточная цитометрия в онкогематологии. Часть II. Основы и нововведения в диагностике хронического лимфолейкоза. Клиническая онкогематология. 2012;5(4):349–54. [Kupryshina NA, Tupitsyn NN. Flow cytometry in oncohematology. Part II. Fundamentals and innovations in chronic lymphocytic leukemia diagnosis. Klinicheskaya onkogematologiya. 2012;5(4):349–54. (In Russ)]

  12. Тупицына Д.Н., Купрышина Н.А., Гривцова Л.Ю. Критерии минимальной остаточной болезни В-клеточного хронического лимфолейкоза в диагностике индолентных лимфом. Вестник гематологии. 2011;7(1):52–3. [Tupitsyna DN, Kupryshina NA, Grivtsova LYu. Criteria for minimal residual disease of B-cell chronic lymphocytic leukemia in the diagnosis of indolent  Vestnik gematologii. 2011;7(1):52–3. (In Russ)]

  13. Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011;117(20):5463–72. doi: 10.1182/blood-2010-12-324210.

  14. Казанский Д.Б. Т-лимфоциты в развитии хронического лимфолейкоза. Клиническая онкогематология. 2012;5(2):85–95.[Kazanskii DB. T-lymphocytes in progression of chronic lymphocytic leukemia. Klinicheskaya onkogematologiya. 2012;5(2):85–95. (In Russ)]

  15. Свирновский А.И. Хронический лимфоцитарный лейкоз: парадигмы и парадоксы. Медицинские новости. 2008;13:7–19. [Svirnovskii AI. Chronic lymphocytic leukemia: paradigms and paradoxes. Meditsinskie novosti. 2008;13:7–19. (In Russ)]

  16. Халафян А.А. Statistica Статистический анализ данных. М.: Бином-Пресс, 2007. 512 c. [Khalafyan AA. Statistika 6. Statisticheskii analiz dannykh. (Statistica 6. Statistical data analysis.) Moscow: Binom-Press Publ.; 2007. 512 р. (In Russ)]

  17. Дубровская Л.И., Князев Г.Б. Компьютерная обработка естественно-научных данных методами многомерной прикладной статистики. Томск: ТМЛ-Пресс, 2011. 120 с. [Dubrovskaya LI, Knyazev GB. Komp’yuternaya obrabotka estestvenno-nauchnykh dannykh metodami mnogomernoi prikladnoi statistiki. (Computer processing of natural science data by methods of multivariate applied statistics.) Tomsk: TML-Press Publ.; 2011. 120 p. (In Russ)]

  18. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325–32. doi: 10.1111/j.1365-2141.2005.05550.x.

  19. Rawstron AC, Bennett FL, O’Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575–83. doi: 10.1056/NEJMoa075290.

  20. Kern W, Bacher U, Haferlach C, et al. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. Br J Haematol. 2012;57(1):86–96. doi: 1111/j.13652141.2011.09010.

  21. Shanafelt TD, Kay NE, Call TG, et al. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count ≥5×109L−1 but a B-cell lymphocyte count <5×109L−1. Leuk Res. 2008;32(9):458–61. doi: 1016/j.leukres.2007.11.030.

  22. Berland R, Wortis HH. Origins and function of B-1 cells with notes on the role of CD5. Ann Rev Immunol. 2002;20(1):253–300. doi: 1146/annurev.immunol.20.100301.064833.

  23. Rawstron AС, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 5% of adults with normal blood counts. Blood. 2002;100(2):635–9. doi: 10.1182/blood.v100.2.635.

  24. Dameshek W. Chronic lymphocytic leukemia-an accumulative disease of immunologically incompetent lymphocytes. Blood. 1967;29(4):566–84. doi: 1182/blood-2016-05-716159.

  25. Zhen JF, Bao F, Zhu MX, et al. Relationship of the changes of peripheral blood immuno-cell subsets with the prognosis of B cell lymphoma patients. Zhongguo Shi Yan XueYe Hue Za Zhi. 2018;26(6):1657–62. doi: 7534/j.issn/1009-2137.2018.06.013.

  26. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;9(3):984–9. doi: 10.1038/nm0997-984.

  27. Ravandi F, O’Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55(2):197–209. doi: 1007/s00262-005-0015-8.

  28. Бадмажапова Д.С., Гальцева И.В., Звонков Е.Е. и др. Особенности экспрессии антигенов, участвующих в формировании иммунологического синапса, при хроническом лимфолейкозе. Онкогематология. 2018;13(1):103–14. doi: 17650/1818-8346-2018-13-1-103-114. [Badmazhapova DS, Galtseva IV, Zvonkov EE, et al. Expression features of antigens involved in the formation of immunological synapse in chronic lymphocytic leukemia. Oncohematology. 2018;13(1):103–14. doi: 10.17650/1818-8346-2018-13-1-103-114. (In Russ)]

  29. Dianzani U, Omede P, Marmont F, et al. Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype. Blood. 1994;83(8):2198–205. doi: 10.1182/blood.V83.8.2198.2198.

  30. Jadidi-Niaragh F, Yousefi M, Memarian A, et al. Increased Frequency of CD8+ and CD4+ Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression. Cancer Invest. 2013;31(2):121–31. doi: 10.3109/07357907.2012.756110.

  31. Mackus WJ, Frakking FN, Grummels A, et al. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood. 2003;102(3):1057–63. doi: 10.1182/blood-2003-01-0182.

  32. Porakishvili N, Roschupkina T, Kalber T, et al. Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exper Immunol. 2001;126(1):29–36. doi: 10.1046/j.1365-2249.2001.01639.x.

  33. Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol. 1997;158(3):1482–9.

  34. de Totero D, Reato G, Mauro F, et al. IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;104(3):589–99. doi: 1046/j.1365-2141.1999.01219.x.

  35. Ticchioni M, Essafi M, Jeandel PY, et al. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene. 2007;50(26):7081–91. doi: 10.1038/sj.onc.1210519.

  36. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;11(3):991–8. doi: 10.1038/ni1102-991.

  37. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112(5):1923–30. doi: 10.1182/blood-2007-05-092882.

  38. Nuckel H, Rebmann V, Durig J, et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105(4):1694–8. doi: 10.1182/blood-2004-08-3335.

  39. Kantor AB, Meril CE, Gercenberg LA, Hillson JL. An unbiased analysis of V-H-D-J(H) sequences from B-1a, B-1b, and conventional B cells. J Immunol. 1997;158(3):1175–86.

  40. Sasson SC, Smith S, Seddiki N, et al. IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine. 2010;50(1):58–68. doi: 10.1016/j.cyto.2009.2.001.

  41. Gaidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432–8. doi: 10.1172/JCI64101.

  42. Lam QLK, Wang S, Ko OKH, et al. Leptin signaling maintains B-cell homeostasis via induction of Bcl-2 and Cyclin D1. Proc Natl Acad Sci USA. 2010;107(31):13812–7. doi: 10.1073/pnas.1004185107.

  43. Мainou-Fowler T, Proctor SJ, Miller S, Dickinson AM. Expression and production of interleukin 4 in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2001;42(4):689–98. doi: 10.3109/10428190109099331.

  44. Majolini MB, D’Elios MM, Galieni P, et al. Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells. Blood. 1998;91(9):3390–6. doi: 10.1182/blood.V91.9.3390.

  45. Frishman J, Long B, Knospe W, et al. Genes for interleukin 7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia. J Exper Med. 1993;177(4):955–64. doi: 1084/jem.177.4.955.

  46. Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol. 2001;112(4):959–64. doi: 10.1046/j.1365-2141.2001.02672.x.

  47. Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CD5-expressing B-lymphocytes from patients with chronic lymphocytic leukemia. J Exper Med. 1989;169(1):255–68. doi: 10.1084/jem.169.1.255.

  48. Ярилин А.А. Иммунология. М.: ГЭОТАР-Медиа, 2010. 752 с. [Yarilin AA. Immunologiya. (Immunology.) Moscow: GEOTAR-Media Publ.; 2010. 752 p. (In Russ)]

  49. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427–37. doi: 10.1172/JCI35017.

  50. Billadeau DD, Burkhardt JK. Regulation of Cytoskeletal Dynamics at the Immune Synapse: New Stars Join the Actin Troupe. 2006;11(7):1451–60. doi: 10.1111/j.1600-0854.2006.00491.x.

  51. Gorgun G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797–805. doi: 10.1172/JCI24176.

  52. Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood. 2008;111(11):5359–70. doi: 1182/blood-2007-08-105395.

  53. D’Arena G, Simeon V, D’Auria F, et al. Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? Am J Blood Res. 2013;3(1):52–7.

  54. Кузьмина Е.Г., Мушкарина Т.Ю., Константинова Т.В. Регуляторные T-лимфоциты (Treg) при лимфопролиферативных заболеваниях. Современная онкология. 2016;18(5):41–2. [Kuzmina EG, Mushkarina TYu, Konstantinova TV. Regulatory T-cells (Treg) in lymphoproliferative diseases. Sovremennaya onkologiya. 2016;18(5):41–2. (In Russ)]

  55. Тупицына Д.Н., Ковригина А.М., Тумян Г.С. и др. Клиническое значение внутриопухолевых FOXP3+ Т-регуляторных клеток при солидных опухолях и фолликулярных лимфомах: обзор литературы и собственные данные. Клиническая онкогематология. 2012;5(3):193–203. [Tupitsyna DN, Kovrigina AM, Tumyan GS, et al. Clinical significance of intratumoral FOXP3+ T-regulatory cells in solid tumors and follicular lymphomas: literature review and own experience. Klinicheskaya onkogematologiya. 2012;5(3):193–203. (In Russ)]

  56. Yang ZZ, Novak AJ, Ziesmer SC, et al. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25– T cells. Blood. 2007;110(7):2537–44. doi: 10.1182/blood-2007-03-082578.

  57. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018–25. doi: 10.1182/blood-2005-02-0642.

  58. Мушкарина Т.Ю., Кузьмина Е.Г., Константинова Т.В., Гривцова Л.Ю. Регуляторные Т-клетки в костном мозге и периферической крови при В-клеточном хроническом лимфолейкозе. Иммунология гемопоэза. 2019;17(2):32–8. [Mushkarina TYu, Kuzmina EG, Konstantinova TV, Grivtsova LYu. Regulatory T-cells in bone marrow and peripheral blood in B-cell chronic lymphocytic leukemia. Immunologiya gemopoeza. 2019;17(2):32–8. (In Russ)]